A striking development in the retatrutide story emerged in June 2026, when Eli Lilly and the FDA allowed a 79-year-old patient to gain extraordinary access to retatrutide through the FDA's compassionate use program. The case, reported by STAT News, has drawn significant attention from the obesity medicine community and from patients who have been closely tracking retatrutide's clinical development. For the tens of thousands of people waiting to access this experimental obesity drug, the story raises important questions about the FDA's compassionate use pathway, Eli Lilly's regulatory posture, and what it all means for the eventual approval timeline.
The FDA's compassionate use program — formally known as Expanded Access — is a regulatory mechanism that allows individual patients to receive investigational drugs outside of a clinical trial when no comparable alternative exists and the potential benefit justifies the risk. It is not a routine pathway. Compassionate use requests require approval from both the drug's manufacturer and the FDA, and they are typically reserved for patients with serious or life-threatening conditions who have exhausted other options.
Retatrutide (also known by its compound identifier LY3437943) is an experimental obesity drug that has not yet received FDA approval and, as of April 2026, an NDA has not yet been filed by Eli Lilly. It is a triple agonist — meaning it simultaneously activates three distinct hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This three-receptor mechanism distinguishes it from currently approved agents and is the basis for the extraordinary weight loss figures seen in clinical trials. In patient communities, it is commonly referred to as reta, and the triple agonist mechanism is sometimes called triple G by those following its development closely.
For compassionate use to apply to a drug like reta, the FDA must be satisfied that the patient's clinical situation is serious enough to warrant access to an unapproved therapy and that the available evidence — in this case, Phase 2 and Phase 3 trial data — supports a reasonable expectation of benefit. The granting of compassionate use does not constitute approval, nor does it create a broader access program for the general public. Each request is evaluated individually.
The details of why this particular 79-year-old patient qualified for compassionate use have not been fully disclosed publicly. What is known is that both Eli Lilly and the FDA approved the request — an unusual alignment that underscores the seriousness of the individual case. As STAT News reported, this type of access to retatrutide outside of a formal trial is genuinely uncommon at this stage of the drug's development.
What the clinical trial data does establish, however, is that the evidentiary basis for granting compassionate use to a high-need patient is substantial. The Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023; NCT04881760) demonstrated that retatrutide produced dose-dependent weight loss of up to 24.2% at 48 weeks at the 12mg dose — in patients who were excluded from the trial if they had type 2 diabetes. At the 8mg dose, 100% of participants achieved at least 5% weight loss, and up to 70% achieved at least 20% weight loss at 48 weeks.
The more recently completed TRIUMPH-4 Phase 3 trial extended those findings considerably. At 68 weeks, participants receiving 12mg retatrutide achieved a mean weight loss of 28.7% — the highest mean weight reduction ever recorded in a Phase 3 obesity trial. To place that in context:
| Drug | Mechanism | Trial | Duration | Mean Weight Loss |
|---|---|---|---|---|
| Semaglutide 2.4mg | GLP-1 agonist | STEP-1 | 68 weeks | ~14.9% |
| Tirzepatide 15mg | GLP-1 / GIP dual agonist | SURMOUNT-1 | 72 weeks | 20.9% |
| Retatrutide 12mg | GLP-1 / GIP / glucagon triple agonist | TRIUMPH-4 (Phase 3) | 68 weeks | 28.7% |
For an older patient with obesity-related comorbidities and limited remaining pharmacological options, these efficacy data — combined with a Phase 2 safety profile that was characterized primarily by dose-dependent gastrointestinal side effects such as nausea, diarrhea, and vomiting — may well support the benefit-risk calculus required for compassionate use approval. The concept of food noise, the persistent intrusive preoccupation with eating that many patients with obesity describe, is something that GLP-1-based triple agonists appear to address through central appetite suppression. For patients in whom dietary intervention alone has repeatedly failed, the urgency of access can be genuinely acute.
It would be premature to read the compassionate use decision as a signal about the FDA's approval timeline. Expanded access decisions are made on a patient-specific basis and are explicitly separate from the NDA review process. As of April 2026, Eli Lilly had not yet filed a New Drug Application for retatrutide, and the peer-reviewed publication of TRIUMPH-4 data remains pending.
That said, the willingness of Eli Lilly to engage with a compassionate use request — requiring internal regulatory and medical resources to evaluate and process — does suggest the company is responding to individual high-need cases even before formal approval. Some observers interpret this as a sign of confidence in the drug's safety and efficacy profile. Others note simply that compassionate use exists precisely for situations like this, and its invocation says nothing definitive about approval timing.
What the case does reinforce is the clinical urgency that surrounds retatrutide for many patients. TRIUMPH-4's 28.7% mean weight loss figure has no precedent in a Phase 3 trial. The Phase 2 data showed meaningful improvements in fasting triglycerides (up to -34.0% at 12mg versus -3.1% for placebo at 24 weeks) and LDL cholesterol (up to -16.9% at the 8mg dose), alongside validated improvements in quality of life scores. For a 79-year-old patient carrying the cardiometabolic burden of obesity, those figures translate into potentially meaningful clinical benefit.
The safety considerations are real. Dysesthesia — an abnormal skin sensation — was reported in 20.9% of participants receiving 12mg in TRIUMPH-4, compared with 0.7% on placebo. Discontinuation rates at the 12mg dose were 18.2%, compared with 4.0% on placebo. These are not trivial numbers and reflect the importance of careful patient selection and dose titration — particularly in older adults.
This case is a reminder that the regulatory pathway for retatrutide is moving forward, even if approval is not yet imminent. The clinical evidence is accumulating, the FDA has demonstrated willingness to engage with the drug on a compassionate use basis, and the Phase 3 data, when published, will form the foundation of a formal NDA submission.
For patients who believe retatrutide may be appropriate for their situation, joining the glp3md waitlist is the most direct way to stay informed as new access options — clinical trials, expanded access programs, or eventual FDA approval — become available. Visit glp3md.com to add your name to the waitlist and receive updates as the regulatory landscape evolves. Please note: joining the waitlist does not guarantee access to retatrutide, a prescription, or any form of treatment. Retatrutide is not FDA-approved, and no promises are made regarding medication availability. The waitlist exists to keep interested patients informed — nothing more, and nothing less.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.